Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

A new study has pitted Wegovy and Zepbound head-to-head in their ability to treat obesity. Published in The New England Journal of Medicine on May 11, the study attempted to analyze the comparative ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study MONDAY, May 12, 2025 (HealthDay News) — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% ...

In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk's Wegovy. The study, published in the New England Journal of ...